David Baker, the recipient of the 2024 Nobel Prize in Chemistry, has joined forces with genomics specialist Jay Shendure to co-head the AI BioDesign initiative. This project is generously supported by a substantial $94.6 million investment from the Paul Allen Legacy Framework. Rather than adhering to the standard approach of training extensive models, the initiative has developed an in-vitro, highly synchronized closed-loop system termed 'design-build-measure-learn'. This innovative system is designed to evaluate millions of artificially crafted DNA sequences—sequences absent in the natural world—simultaneously, thereby synchronizing the pace of AI-generated designs with the experimental verification prowess of synthetic biology.

Through a series of experiments, the project has accumulated vast quantities of proprietary data for the models, effectively bridging the void left by natural samples. AI BioDesign eschews the pursuit of versatile large models; instead, all its discoveries will be entirely accessible and shared with the broader scientific community. Concurrently, the project is advocating for the establishment of a registration and archiving system for artificially synthesized DNA to mitigate potential misuse risks.

The project sets its sights on achieving significant advancements within the next 18 to 24 months and aims to extend its resources to researchers worldwide within five years. Its overarching objective is to delve into the realm of molecules, such as proteins, that have never before existed in nature, to unlock biological design spaces untouched by natural evolution, and to propel groundbreaking innovations in fields like novel disease therapies, enzymes capable of degrading plastics, and energy-efficient biological computers.